novo nordisk's semaglutide failed to slow alzheimer's disease progression patients treated with the GLP-1 receptor agonist (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according Novo Nordisk testing its blockbuster
Description
4, Supplementary Table 1)
J Cell Biol 217:22732289
DellIsola, A., Recenti, F., Englund, M
MASH was formerly known as nonalcoholic steatohepatitis (NASH)
Researchers from Oxford University analyzed 37 studies that examined what happened when people stopped taking weight loss drugs
[1] [2] Patients who experience pronounced nausea may prefer evening administration, while those who experience minimal gastrointestinal effects may prefer morning dosing to avoid any potential sleep disruption
